Michael K. Borre, Ph.D.
Affiliations: | 2011 | Mechanical Engineering | University of Southern California, Los Angeles, CA, United States |
Area:
Mechanical EngineeringGoogle:
"Michael Borre"Parents
Sign in to add mentorHenryk Flashner | grad student | 2011 | USC | |
(Periodic solutions of flexible systems under discontinuous control.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Fredsøe J, Glud E, Boesen L, et al. (2023) Danish Prostate Cancer Consortium Study 1 (DPCC-1) protocol: Multicentre prospective validation of the urine-based three-microRNA biomarker model uCaP. Bmj Open. 13: e077020 |
Fredsøe J, Sandahl M, Vedsted P, et al. (2023) Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population. European Urology Oncology |
Borre M, Brodersen JB, Jacobsen H, et al. (2023) [Not Available]. Ugeskrift For Laeger. 185 |
Fredsøe J, Rasmussen M, Tin AL, et al. (2022) Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine. Scientific Reports. 12: 15193 |
Siltari A, Riikonen J, Koskimäki J, et al. (2022) Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. Bmj Open. 12: e050264 |
Salachan PV, Rasmussen M, Fredsøe J, et al. (2022) Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Medicine. 14: 9 |
Riedel M, Berthelsen MF, Cai H, et al. (2021) In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. Oncogene |
Haldrup J, Strand SH, Cieza-Borrella C, et al. (2020) FRMD6 has tumor suppressor functions in prostate cancer. Oncogene |
Nguyen-Nielsen M, Møller H, Tjønneland A, et al. (2019) Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiology. 64: 101623 |
Nørgaard M, Haldrup C, Bjerre MT, et al. (2019) Epigenetic silencing of MEIS2 in prostate cancer recurrence. Clinical Epigenetics. 11: 147 |